Mok CC, et al. - Adult SLE persons who had a SLEDAI < 6 and stable immunosuppressive treatment for ≥ 6 months were enrolled (n = 90) in this randomized placebo-controlled trial in order to examine the safety and immunogenicity of live-attenuated herpes zoster (HZ) vaccine in individuals with SLE. Individuals were randomized to receive the HZ vaccine (Zostavax) or placebo injection. It was discovered that in individuals with stable SLE not receiving intensive immunosuppression, Zostavax was well-endured and stimulated an immune response.